Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 5,456 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor Malignancies, Cancer Clear all
Completed Phase 2 Interventional Results available

Eribulin and Lenvatinib in Advanced Solid Tumors

NCT02640508
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Eribulin, Lenvatinib
Drug
Lead sponsor
Virginia G. Kaklamani
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 24, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients

NCT01915576
View directory record Official record
Conditions
Neoplasms
Interventions
BAY1125976
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Santa Monica, California • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 24, 2026, 5:33 AM EDT
Not listed No phase listed Observational

Universal Germline Testing in the Community

NCT05416710
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Tumor, Adult
Interventions
Invitae's 84 gene multi-cancer panel.
Diagnostic Test
Lead sponsor
Invitae Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 24, 2026, 5:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
NKTR-255, Cetuximab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 24, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis

NCT00855803
View directory record Official record
Conditions
Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
radiation
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 24, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional Results available

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

NCT02002689
View directory record Official record
Conditions
PTCH1 or SMO Activated Solid and Hematologic Tumors
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Greenwood Village, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 24, 2026, 5:33 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
Interventions
225Ac-ETN029, 111In-ETN029
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Recruiting No phase listed Observational

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

NCT02530658
View directory record Official record
Conditions
Solid, Liquid, Central Nervous System Tumors
Interventions
Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, Return of Results Follow-Up Visits, Blood Sample, Skin Biopsy
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2053
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

NCT04471415
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Interventions
DRP-104, atezolizumab
Drug · Biological
Lead sponsor
Dracen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 24, 2026, 5:33 AM EDT
Recruiting Phase 1 Interventional

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

NCT06096974
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
YL-17231
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 24, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
MT-6402
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 24, 2026, 5:33 AM EDT
Terminated Not applicable Interventional Results available

Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer

NCT00217724
View directory record Official record
Conditions
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
glutamine, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 24, 2026, 5:33 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

NCT05068024
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
FWD1509 MsOH
Drug
Lead sponsor
Forward Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Canton, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 24, 2026, 5:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT06357988
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Radionuclide Imaging, Vismodegib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Recruiting Phase 1 Interventional

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

NCT05627960
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
Interventions
AG-01 Compound
Drug
Lead sponsor
A&G Pharmaceutical Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 24, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer

NCT01571024
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Interventions
BKM120, mFOLFOX6
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 24, 2026, 5:33 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059
View directory record Official record
Conditions
Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Interventions
ALTA2618
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
La Jolla, California • Denver, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Not listed Phase 1 Interventional

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

NCT05525559
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ET0038
Drug
Lead sponsor
Etern BioPharma (Shanghai) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 24, 2026, 5:33 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

NCT05676489
View directory record Official record
Conditions
Healthy Volunteers, Recurrent Glioma, Brain Metastases From Extra-cranial Solid Tumors
Interventions
[F-18]MeFAMP PET
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Months to 89 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

NCT00345189
View directory record Official record
Conditions
Tumors, Lymphoma
Interventions
CNF2024
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • New Haven, Connecticut • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Oct 24, 2026, 5:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Assess AFM24 in Advanced Solid Cancers

NCT04259450
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 24, 2026, 5:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

NCT04379518
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Recruiting No phase listed Observational

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

NCT05530759
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Specimen, Biospecimen Collection, Archived Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Results available

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

NCT03364049
View directory record Official record
Conditions
Solid Neoplasms
Interventions
MK-7162, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Santa Monica, California • Grand Rapids, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 24, 2026, 5:33 AM EDT